Psychedelics on the cusp of market breakthrough as clinical, policy support grow https://www.biospace.com/drug-devel...-breakthrough-as-clinical-policy-support-grow
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts https://www.biospace.com/drug-devel...kers-as-definium-compass-near-major-catalysts
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout https://www.biospace.com/drug-devel...alyst-expectations-in-phase-3-anxiety-readout
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial https://www.psychiatrictimes.com/vi...lief-for-generalized-anxiety-in-phase-3-trial DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.
Psychedelics developer Definium scores more positive data for LSD pill https://www.biopharmadive.com/news/definium-lsd-psychedelics-trial-results-gad-anxiety/827669/ Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.
Definium says LSD-based pill reduces anxiety in late-stage study https://www.reuters.com/business/he...-reduces-anxiety-late-stage-study-2026-08-12/ Aug 12 (Reuters) - Definium Therapeutics' (DFTX.O), opens new tab LSD-based experimental pill exceeded investor expectations by significantly reducing anxiety symptoms in a late-stage study, meeting the trial's main goal, the company said on Wednesday.
After today’s positive Phase 3 VOYAGE results in GAD, I think the risk profile around DT120 has changed substantially. We now have two successful Phase 3 trials using the same 100 µg dose across two major psychiatric indications, MDD and GAD. Both produced highly significant efficacy, rapid onset and durable benefit, without a new safety signal that materially changes the thesis. At this point, the question of whether pharmaceutical LSD can produce a meaningful therapeutic effect in a rigorous Phase 3 setting has been answered much more convincingly. Rob Barrow’s comments on this morning’s call were also important. Management does not appear overly concerned about the September PANORAMA study and its 50 µg arm because they believe the evidence already generated provides a compelling basis for the regulatory package. PANORAMA still matters, particularly as another GAD replication and because its active-control design addresses some of the questions around functional unblinding, but it no longer feels like an existential test of whether DT120 works. A second positive GAD Phase 3 would strengthen an already convincing efficacy story rather than create it from scratch. There are still regulatory questions around the total safety database, labeling, supervised administration, controlled-substance requirements and ultimately how a several-hour treatment session is implemented commercially. PANORAMA and the remaining MDD program also matter. But those are very different risks from questioning whether the underlying drug has real efficacy. As a long-term holder, that distinction matters to me. I would describe DT120 today as "highly de-risked clinically and substantially de-risked from an approval standpoint", while recognizing that commercial execution remains an important unknown. DFTX has progressed from having an interesting psychedelic candidate to having a drug that has demonstrated Phase 3 efficacy in both depression and anxiety. If PANORAMA is also positive in September, the regulatory case for GAD becomes a lock, but I think the larger shift has already occurred: the debate is increasingly moving away from whether DT120 works and toward how it gets approved, implemented and ultimately commercialized.
LSD Just Passed Its Biggest Trial Yet for Anxiety https://gizmodo.com/lsd-just-passed-its-biggest-trial-yet-for-anxiety-2000797652 It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential https://www.investing.com/news/anal...uy-on-psychedelic-drug-potential-93CH-4864028
$DFTX Targets JonesTrading — $90 Bank of America — $75 Baird — $75 Piper Sandler — $75 Wells Fargo — $72 H.C. Wainwright — $70 Oppenheimer — $70 Needham — $66 RBC Capital — $66 Canaccord Genuity — $64 LifeSci Capital — $63 Stifel — $60
Definium reports positive results for anxiety treatment https://pharmatimes.com/news/definium-reports-positive-results-for-anxiety-treatment/
Newsweek - VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans https://www.newsweek.com/va-benefit...chedelic-drug-treatment-for-veterans-12344625
DFTX Public Comments on the Request for Information: Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settings https://www.regulations.gov/comment/HRSA-2026-0034-0040 -- Definium’s HRSA RFI response argues that any future psychedelic-care framework should treat DT120 like other FDA-approved CNS medicines: requirements should be product-specific, evidence-based, and tied to the actual safety profile, rather than imposing a blanket psychedelic model. Definium explicitly rejects mandatory psychotherapy, psychedelic-specific licensure, and automatic two-monitor staffing. It supports competency-based training, telehealth for screening/prescribing/follow-up, separation of prescribers from session monitors, and use of a single appropriately trained licensed monitor when clinically appropriate. Commercially, the submission is aimed at making DT120 scalable in ordinary outpatient and rural settings. Definium says a physician should not have to remain onsite for the full session, clinics should avoid burdensome new certification schemes, and AI/digital tools may eventually augment monitoring. Its preferred operating model is essentially one trained monitor per patient, shared on-call medical coverage, structured discharge criteria, and telehealth around the treatment session. Definium says this could roughly double clinic throughput versus a two-monitor/continuous-physician model, which directly addresses one of the biggest concerns around DT120’s roughly six-hour treatment duration.
Radial Now Supports the Country's Largest Brain Medicine Clinical Network, Expanding Access to Breakthrough Treatments https://www.prnewswire.com/news-rel...atments-302855839.html?utm_source=chatgpt.com --- On August 20, 2026, Radial Health announced that it acquired the management-services organization supporting Mindful Health Solutions, creating what Radial describes as the largest U.S. “brain medicine” clinical network: 27 clinics, 100+ clinicians, and hundreds of thousands of patients, with explicit plans to offer psychedelic medicines in the near future. Mindful is already a major interventional-psychiatry operator and the second-largest U.S. administrator of Spravato, with established reimbursement relationships spanning Medicare, Tricare, VA-CCN, Aetna, Cigna, United and multiple Blue plans. Radial’s announcement specifically identifies COMP360 psilocybin among the emerging treatments the network is preparing to support.
Why pharmaceutical companies are interested in psychedelics https://www.marketplace.org/story/2026/08/20/why-big-pharma-wants-in-on-the-psychedelics-business
The White House’s MAHA Gatekeeper - https://www.theatlantic.com/politics/2026/07/heidi-overton-maha-rfk/688038/?utm_source=apple_news Almost tailor-made for $DFTX FDA-regulated, conventional pharmaceutical development programs with randomized Phase 3 trials, defined doses, standardized manufacturing, safety databases, and eventual NDAs
ASU-led project to examine psychedelic therapy for mental health https://news.asu.edu/20260821-healt...ect-examine-psychedelic-therapy-mental-health ASU is partnering with the U.S. Department of Veterans Affairs, Definium Therapeutics and Sunstone Therapies on the project. $DFTX
